NASDAQ:DTIL Precision BioSciences Q1 2026 Earnings Report $6.94 +0.03 (+0.36%) As of 03:26 PM Eastern This is a fair market value price provided by Massive. Learn more. ProfileEarnings HistoryForecast Precision BioSciences EPS ResultsActual EPS-$0.75Consensus EPS -$0.66Beat/MissMissed by -$0.10One Year Ago EPSN/APrecision BioSciences Revenue ResultsActual Revenue$10.84 millionExpected Revenue$4.05 millionBeat/MissBeat by +$6.79 millionYoY Revenue GrowthN/APrecision BioSciences Announcement DetailsQuarterQ1 2026Date5/5/2026TimeBefore Market OpensConference Call DateTuesday, May 5, 2026Conference Call Time9:30AM ETUpcoming EarningsPrecision BioSciences' Q2 2026 earnings is estimated for Thursday, August 6, 2026, based on past reporting schedules, with a conference call scheduled on Friday, July 31, 2026 at 9:30 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Precision BioSciences Earnings HeadlinesPrecision BioSciences Announces New and Late-Breaking PBGENE-HBV Clinical Data from the ELIMINATE-B Study at European Association for the Study of the Liver Congress 2026May 27 at 2:30 AM | businesswire.comPrecision BioSciences Touts Gene-Editing Momentum, Cash Runway Through 2028May 25, 2026 | americanbankingnews.comYour book is insideThe "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. They don't know the rules. They don't know what to avoid. And they hand their account to Wall Street on a silver platter. Normally $29.97. Free today.May 29 at 1:00 AM | Profits Run (Ad)Precision BioSciences to Host Investor Webcast to Discuss Late-Breaking PBGENE-HBV Data from ELIMINATE-B Trial Presented at European Association for the Study of the Liver ...May 22, 2026 | uk.finance.yahoo.comPrecision BioSciences to Host Investor Webcast to Discuss Late-Breaking PBGENE-HBV Data from ELIMINATE-B Trial Presented at European Association for the Study of the Liver Congress 2026May 21, 2026 | businesswire.comPrecision BioSciences Presents New Preclinical Data Supporting the Advancement of PBGENE-DMD into Clinic at the American Society of Gene & Cell Therapy 2026 Annual MeetingMay 14, 2026 | businesswire.comSee More Precision BioSciences Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Precision BioSciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Precision BioSciences and other key companies, straight to your email. Email Address About Precision BioSciencesPrecision BioSciences (NASDAQ:DTIL) is a clinical‐stage genome editing company that leverages its proprietary ARCUS platform to develop targeted gene therapies. ARCUS, an engineered nuclease derived from a naturally occurring enzyme, enables precise DNA modifications for both in vivo and ex vivo applications. The company’s pipeline spans genetic diseases—including rare monogenic disorders—and immuno‐oncology, where it is advancing allogeneic cell therapy candidates designed to address hematologic malignancies and solid tumors. Founded in 2006 as a spin‐out from research at the University of North Carolina, Precision BioSciences is headquartered in Durham, North Carolina, with additional research and manufacturing capabilities located in the Research Triangle Park area. The company completed a business combination with a special purpose acquisition company (SPAC) in 2021 and began trading on the Nasdaq under the ticker DTIL. Over its history, Precision BioSciences has focused on optimizing ARCUS for high specificity, efficiency and manufacturability, laying the groundwork for scalable gene editing solutions. Precision BioSciences is led by President and Chief Executive Officer Matt Kane, who has steered the company’s scientific and strategic initiatives since joining in 2014. Under his leadership, the company has established collaborations with academic institutions and biopharmaceutical partners to advance preclinical studies and clinical trials. With a focus on innovation and translational research, Precision BioSciences aims to bring next‐generation gene therapies from discovery through to regulatory approval and commercialization.View Precision BioSciences ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Shares Fall, Targets Rise—Markets and Analysts Diverge on SynopsysDollar Tree Keeps Winning After Family Dollar DivorceSalesforce Stock Finds Support as AI Momentum BuildsMarvell’s Pullback May Be the Setup Bulls Were Waiting ForSnowflake and the Snowballing Impact of its AI FlywheelPalomar’s High-Risk Insurance Strategy Is Paying Off BigThis Quantum Computing Stock May Be Closer to a Breakout Than You Think Upcoming Earnings Hewlett Packard Enterprise (6/1/2026)Palo Alto Networks (6/2/2026)Broadcom (6/3/2026)CrowdStrike (6/3/2026)Medtronic (6/3/2026)Ciena (6/4/2026)Oracle (6/10/2026)Adobe (6/11/2026)Accenture (6/18/2026)FedEx (6/23/2026) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
